Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survival

Molecular Metabolism

Volumn 5, Issue 8, 2016, Pages 731-736

  Neumann, Ursula H ^a   Ho, Jessica S S ^a   Mojibian, Majid ^a   Covey, Scott D ^a   Charron, Maureen J ^b   Kieffer, Timothy J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Glucagon; Glucose metabolism; Insulin; Lipid metabolism; Mice; Type 1 diabetes

Indexed keywords

FATTY ACID; GLUCAGON RECEPTOR; GLUCOSE; INSULIN; KETONE; LEPTIN; TRIACYLGLYCEROL;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FEMALE; GENE DELETION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; KNOCKOUT MOUSE; LIPID METABOLISM; LIPID STORAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84989935619     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.05.014     Document Type: Article

References (18)

1. [1] Muller, W.A., Faloona, G.R., Unger, R.H., Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. The American Journal of Medicine 54 (1973), 52–57.
2. [2] Reaven, G.M., Chen, Y.D., Golay, A., Swislocki, A.L., Jaspan, J.B., Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism 64 (1987), 106–110.
3. [3] Lee, Y., Wang, M.Y., Du, X.Q., Charron, M.J., Unger, R.H., Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60 (2011), 391–397.
4. [4] Lee, Y., Berglund, E.D., Wang, M.Y., Fu, X., Yu, X., Charron, M.J., et al. Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proceedings of the National Academy of Sciences of the United States of America 109 (2012), 14972–14976.
5. [5] Wang, M.Y., Yan, H., Shi, Z., Evans, M.R., Yu, X., Lee, Y., et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proceedings of the National Academy of Sciences of the United States of America 112 (2015), 2503–2508.
6. [6] Jun, L.S., Millican, R.L., Hawkins, E.D., Konkol, D.L., Showalter, A.D., Christe, M.E., et al. Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production. Diabetes 64 (2015), 819–827.
7. [7] Gelling, R.W., Du, X.Q., Dichmann, D.S., Romer, J., Huang, H., Cui, L., et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America 100 (2003), 1438–1443.
8. [8] Brand, C.L., Jorgensen, P.N., Svendsen, I., Holst, J.J., Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45 (1996), 1076–1083.
9. [9] Duvillie, B., Cordonnier, N., Deltour, L., Dandoy-Dron, F., Itier, J.M., Monthioux, E., et al. Phenotypic alterations in insulin-deficient mutant mice. Proceedings of the National Academy of Sciences of the United States of America 94 (1997), 5137–5140.
10. [10] Neumann, U.H., Denroche, H.C., Mojibian, M., Covey, S.D., Kieffer, T.J., Insulin knockout mice have extended survival but volatile blood glucose levels on leptin therapy. Endocrinology 157 (2016), 1007–1012.
11. [11] Huynh, F.K., Levi, J., Denroche, H.C., Gray, S.L., Voshol, P.J., Neumann, U.H., et al. Disruption of hepatic leptin signaling protects mice from age- and diet-related glucose intolerance. Diabetes 59 (2010), 3032–3040.
12. [12] Wrann, C.D., Rosen, E.D., New insights into adipocyte-specific leptin gene expression. Adipocyte 1 (2012), 168–172.
13. [13] Laron, Z., Insulin–a growth hormone. Archives of Physiology and Biochemistry 114 (2008), 11–16.
14. [14] Unger, R.H., Cherrington, A.D., Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. Journal of Clinical Investigation 122 (2012), 4–12.
15. [15] Yu, R., Dhall, D., Nissen, N.N., Zhou, C., Ren, S.G., Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS One, 6, 2011, e23397.
16. [16] Meek, T.H., Dorfman, M.D., Matsen, M.E., Fischer, J.D., Cubelo, A., Kumar, M.R., et al. Evidence that in uncontrolled diabetes, hyperglucagonemia is required for ketosis but not for increased hepatic glucose production or hyperglycemia. Diabetes 64 (2015), 2376–2387.
17. [17] Steenberg, V.R., Jensen, S.M., Pedersen, J., Madsen, A.N., Windelov, J.A., Holst, B., et al. Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes. Diabetologia 59 (2016), 363–370.
18. [18] Damond, N., Thorel, F., Moyers, J.S., Charron, M.J., Vuguin, P.M., Powers, A.C., et al. Blockade of glucagon signaling prevents or reverses diabetes onset only if residual beta-cells persist. eLife, 5, 2016.